Goodwill
£000
Software
£000
Development costs
£000
Patent rights
£000
Marketing authorisations
£000
Acquired intangibles
£000
Total
£000
Cost
At 1 July 201549,3265,66310,6403,680853185,614255,776
Additions2,7965701,3374,703
Acquisitions through business combinations52,323108122,145174,576
Impairment(151)(1,537)(4,277)(5,965)
Foreign exchange adjustments11,53075259236,69949,573
At 30 June 2016 and 1 July 2016 (restated)113,1799,16810,2655,017853340,181478,663
Additions3,2371,25829910434,18339,081
Acquisitions through business combinations9,9067821,32331,307
Disposals(100)(317)(417)
Foreign exchange adjustments5,04934948813,66819,554
At 30 June 2017128,13412,73211,6945,316957409,355568,188
Accumulated Amortisation
At 1 July 20152,2265,2982,13879,43089,092
Charge for the year20279640520,14921,552
Impairment(151)(1,319)(333)(1,803)
Foreign exchange adjustments26435413,94614,564
At 30 June 2016 and 1 July 2016 (restated)2,5415,1292,543113,192123,405
Charge for the year37598458340,44442,386
Disposals(96)(12)(108)
Foreign exchange adjustments102316,1106,243
At 30 June 20172,9226,1443,126159,734171,926
Net book value
At 30 June 2017128,1349,8105,5502,190957249,621396,262
At 30 June 2016 (restated)113,1796,6275,1362,474853226,989355,258
2017
£000
2016
£000
Software assets in the course of construction included above9,4031,451

The asset within patent rights comprises payments to acquire the right to develop and market Trilostane, the active ingredient of Vetoryl Capsules, for animal health applications in the USA and Canada. The carrying value at 30 June 2017 was £0.3 million with a remaining amortisation period of 1.5 years. The rights to Equidone, which was launched in the US during 2011, has a carrying value of £0.4 million with a remaining amortisation period of 4 years. The in-licensed products within EU and Canada acquired in 2016 had a carrying value of £0.7 million and £0.4 million respectively, with remaining amortisation periods of 3.5 years and 8.5 years respectively. During the year, £0.3 million was added to patent rights for new in-licenced products within EU, with a remaining amortisation period of 4.5 years.

£0.8 million of the marketing authorisations relate to the Vetivex range of products. Ownership of the marketing authorisations rests with the Group in perpetuity. There are not believed to be any legal, regulatory or contractual provisions that limit their useful lives. Vetivex is an established range of products which are relatively simple in nature and there are a limited number of players in the market. Accordingly, the Directors believe that it is appropriate that the marketing authorisations are treated as having indefinite lives for accounting purposes.

Goodwill is allocated across cash generating units that are expected to benefit from that business combination. Key assumptions made in this respect are given in note 14.

In accordance with the disclosure requirements of IAS 38 'Intangible Assets', the components of acquired intangibles are summarised below:

Commercial relationships
£000
Pharmacological process
£000
Brand
£000
Capitalised development costs
£000
Product
rights
£000
Total
£000
Cost
At 1 July 201520,719164,895185,614
Acquired through business combinations1,37045,46411,54663,765122,145
Impairment(4,277)(4,277)
Foreign exchange adjustments1923,3718868,59723,65336,699
At 30 June 2016 and 1 July 2016 (restated)1,56248,83512,43293,081184,271340,181
Additions34,18334,183
Acquisitions through business combinations37417,9562,99321,323
Foreign exchange adjustments1261,7124413,4627,92713,668
At 30 June 20171,68850,54713,247114,499229,374409,355
Accumulated Amortisation
At 1 July 20156,00973,42179,430
Charge for the year1887593093,36715,52620,149
Impairment(333)(333)
Foreign exchange adjustments1955241,29712,55113,946
At 30 June 2016 and 1 July 2016 (restated)20781433310,673101,165113,192
Charge for the year35811,4411,9849,10217,55940,444
Disposals(12)(12)
Foreign exchange adjustments20(172)(23)6435,6426,110
At 30 June 201757312,0832,29420,418124,366159,734
Net book value
At 30 June 20171,11538,46410,95394,081105,008249,621
At 30 June 2016 (restated)1,35548,02112,09982,40883,106226,989

The table below provides further detail on the acquired intangibles and their remaining amortisation period.

Significant assetsDescriptionCarrying value £'000Sub-Total carrying value £'000Remaining amortisation period
Intangible assets arising from the acquisition of VetXX Holding A/SProduct, marketing and distribution rights4,8554,855½ year
Intangible assets arising from the acquisition of DermapetProduct, marketing and distribution rights26,18326,1838 ½ years
Intangible assets arising from the acquisition of GenetrixProduct, marketing and distribution rights1,9121,9123 ½ years
Intangible assets arising from the acquisition of EurovetTechnology, product, marketing and distribution rights41,58541,5855 years
Intangible assets arising from the acquisition of PSPC IncProduct, marketing and distribution rights4,5174,5177 years
Intangible asset acquired from Pharmaderm Animal HealthMarketing and distribution rights8388385 years
HY-50 intangible asset acquired from Bexinc LimitedMarketing and distribution rights2,3442,3444 ½ years
Intangible assets arising from the acquisition of GeneraProduct, brand, technology, marketing and distribution rights1,2865 ½ years
4708 ½ years
8,57213 ½ years
10,328Genera – total
Intangible assets arising from the acquisition of PutneyProduct, brand, technology, pharmacological process, marketing and distribution rights10,1789 years
38,4789 years
56,14611 years
104,802Putney – total
Intangible asset arising from the acquisition of ApexProduct and technology16,34216 years
3,00313 years
19,345Apex - total
Intangible asset relating to Animal EthicsMarketing and distribution rights29,07929,07910 years
Intangible assets relating to a US dental licensing agreementMarketing and distribution rights3,8323,83310 years
249,621